Meaning emerges
from many small signals.
physician-scientist · modeler · reluctant writer
Reading disease as a system, where a single readout means little but the pattern across thousands means everything.
microbiome
& disease
& disease
immuno-
oncology
oncology
pharmacometrics
· QSP
· QSP
subthreshold signals
Ideas not yet fired
I am drawn to problems where biology behaves as a system: the informative signal often lies in the interactions between components rather than in any single readout.
This section holds ideas that are still below threshold: themes I keep returning to, noted here as framings rather than protocols. Some may develop into studies; most will not, which is the expected base rate for early ideas.
signal 01 · noted 2026-08
Mechanism, then model
Trials that pair clinical endpoints with biomarker assessments on a domain framework can answer whether an intervention works and, indirectly, what the response mechanism might be.
signal 02 · noted 2026-08
Low-cost molecules, hard endpoints
Off-patent, low-cost therapeutics (micronutrients, repurposed generics) rarely receive adequately powered evaluation, though preclinical evidence for several would justify trials against clinically meaningful endpoints.
signal 03 · noted 2026-08
The gut as a bioreactor
The gut can be read as an electrochemical system, where operating conditions such as redox potential and pH influence which microbial communities establish, with consequences for mucosal disease.
signal 04 · noted 2026-08
PK-guided precision medicine
Therapeutic drug monitoring and population pharmacokinetic models could individualize dosing where fixed regimens underperform, a form of precision medicine grounded in drug exposure rather than genomics alone.
signal 05
potentiating
signal 06
summating
These notes are kept deliberately brief; the framings are public while the working detail is not. If any of them intersect with your work, I would be glad to discuss further.
research
Selected work
Where the signals crossed threshold. One published map, one oncobiome, one trial in flight.
featured · microbiome & disease
Mapping the microbiome-redox spectrum in chronic gastritis
Peptic ulcers are usually read through pH. We read them through redox instead: mapping microbial signatures in ulcer versus non-ulcer dyspepsia against the redox potential of their micro-environment, and proposing a Microbial-Redox Index as a diagnostic handle and a route to redox-targeted pre- and probiotics.
Microbiome-linked transcriptomic signatures in NMIBC
Bladder tumors live in constant contact with their own microbial neighbourhood. Meta-transcriptomics of the native oncobiome in non-muscle invasive bladder cancer, linked to host transcriptional programs, a step toward personalized uro-oncology. Urologic Oncology, 2026.
read →
DREAM-BiG: adjunctive magnesium bisglycinate in depression
A randomized, double-blind, placebo-controlled trial, designed and run as my MD thesis. Clinical scales paired with mechanistic biomarkers, BDNF, magnesium, glycine, to ask not just whether it works but why.
read →
noise
Noise
Short notes on findings, methods, and things I am reading. Signal's overrated.
Loading…
about
Abhishek Akella
I was drawn to research by a simple fascination: the gut as a living ecosystem, not a static organ. My pursuit began at the bench rather than the classroom, in the early years of my MBBS, as an undergraduate research assistant in a microbiome lab.
Four years of that curiosity became a published map of the microbiome-redox spectrum in chronic gastritis. It taught me to read clinical problems as systems-level puzzles rather than single-pathway deficits.
Working in acute care showed me the other side of the equation: patients whose suffering outran the available therapeutics. That duality, the restlessness of a clinician and the rigor of a bench scientist, is what pulled me into MD Pharmacology. The discipline rewards parallel thinking: a receptor mechanism to a clinical outcome, a nutrient deficiency to a neurotransmitter imbalance.
My MD thesis, the DREAM-BiG trial (Depression REsponse to Adjunctive Magnesium Bis Glycinate), lives exactly there: a randomized, double-blind, placebo-controlled trial pairing clinical scales with biomarkers to move past symptom counting toward why an intervention works.
As an early-career scientist, I aim to build solutions matched to the cause and the scale of the problem, bridging science from lab to bedside.
tap to resolve